Skip to main content

Table 1 Epidemiologic and clinical baseline characteristics of the cohort

From: Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus

  LLDAS (208/259, 80.3%) Active (51/259, 19.7%) p value
Median age at enrollment (years) (IQR) 47 (38.5–55) 38 (30–47) p < 0.001
Median disease duration (years) (IQR) 15 (7–21) 9 (5–17) p = 0.052
Ethnicity (% of Caucasian) 98.6% 96.1% ns
Sex (% of female) 92.3% 96.1% ns
Median SELENA-SLEDAI at enrollment (IQR) 2 (0–2) 6 (5–8) p < 0.0001
Median SLICC-DI at enrollment (IQR) 1 (0–2) 0 (0–1) ns
Fibromyalgia (% of patients) 12% 5.9% ns
Cumulative renal involvement (% of patients) 42.8% 47% ns
Cumulative cutaneous involvement (% of patients) 51.9% 66.7% p = 0.062
Cumulative articular involvement (% of patients) 66.3% 76.5% ns
Cumulative serositic involvement (% of patients) 19.2% 19.6% ns
Cumulative haematological involvement (% of patients) 49% 66.7% p = 0.026
Cumulative neuropsychiatric involvement (% of patients) 12.5% 7.8% ns
Ongoing GC (% of patients) 44.2% 78.4% p < 0.001
Median daily GC dose (mg methylprednisolone) (IQR) 0 (0–4) 4 (2–8) p < 0.0001
Ongoing immunosuppressant (% of patients) 39.4% 62.7% p = 0.003
Ongoing HCQ (% of patients) 78.4% 76.5% ns